CDKN2A and cancer: Recent studies found that genomic CDKN2A loss-of-function is associated with worse clinical outcome in patients treated with cancer immunotherapy in multiple cancer types (Adib et al., 2021; Gutiontov et al., 2021; Zhu et al., 2021).